Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients (Q33503017)

27 July 2017

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients (English)

1 reference

27 July 2017

hepatocellular carcinoma

1 reference

1 reference

1 reference

Chao Y

1

1 reference

27 July 2017

Chan WK

2

1 reference

27 July 2017

Birkhofer MJ

3

1 reference

27 July 2017

Hu OY

4

1 reference

27 July 2017

Wang SS

5

1 reference

27 July 2017

Huang YS

6

1 reference

27 July 2017

Liu M

7

1 reference

27 July 2017

Whang-Peng J

8

1 reference

27 July 2017

Chi KH

9

1 reference

27 July 2017

Lui WY

10

1 reference

27 July 2017

Lee SD

11

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

British Journal of Cancer

27 July 2017

1 reference

27 July 2017

78

1 reference

27 July 2017

34-39

1 reference

27 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.438

27 July 2017

0 references

cites work

Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Treatment of hepatocellular carcinoma: too many options?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Clinical toxicities encountered with paclitaxel (Taxol).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Taxol: mechanisms of action and resistance.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Taxol: pharmacology, metabolism and clinical implications.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan

31 October 2018

1 reference

12 December 2020

Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function

1 reference

12 December 2020

Expression of a multidrug resistance gene in human cancers

1 reference

12 December 2020

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

1 reference

12 December 2020

High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma

1 reference

12 December 2020

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

1 reference

12 December 2020

Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function?

1 reference

12 December 2020

The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.438

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference